人脑胶质瘤GDNF基因启动子I区H3组蛋白乙酰化修饰情况

目的：明确GDNF启动子I区在人脑胶质瘤中H,赖氨酸残基9位乙酰化（H3K9Ac）情况,探讨其对于GDNF在胶质瘤中表达的影响。方法：RT-PCR检测各组中GDNFmRNA的表达;建立基于Real．timePCR分析的染色质免疫共沉淀（CHIP）方法,检测12例胶质瘤与6例正常脑组织中GDNF基因启动子I区王H3组蛋白乙酰化情况。结果：Real-timePCR验证人脑胶质瘤GDNFmRNA的表达,转录水平随级另q的增高而增高,且低级别组、高级别组与正常组之间存在显著的统计学差异（P〈0．05）。启动子I区的H,组蛋白乙酰化水平,正常组与低级别组和高级别组之间比较均有显著性差异（P〈0．05）,且低级别与高级别之间也有显著性差异。结论：在人脑胶质瘤组织中,GDNF启动子I区发生了H3组蛋白高乙酰化修饰,这种修饰很可能会影响GDNF基因的表达。     

MMP-9和PTEN在胶质瘤中的表达及相关性分析

目的：检测脑胶质瘤组织中MMP-9和PTEN表达情况并探讨其意义。方法：采用免疫组织化学S-P法检测50例脑胶质瘤、10例正常脑组织中两者的表达。结果：脑胶质瘤组织中MMP一9和PTEN表达定位于细胞浆,其阳性表达率分别为74．00％（37／50）和60．00％（30／60）与正常脑组织0、100％有差异（P〈0．05）。两者的表达与胶质瘤患者的年龄、性别无明显相关性（P〉O．05）,但高级别组与低级别组之间表达有差异,具有统计学意义（P〈0．05）;在脑胶质瘤组织中MMP-9蛋白的阳性表达与PTEN蛋白的阳性表达有相关性,二者呈负相关（P〈0．05）。结论：MMP．9蛋白在胶质瘤组织中的表达明显高于正常脑组织,并且高级别胶质瘤组的表达明显高于低级别胶质瘤组中的表达,提示MMP-9可能与胶质瘤的浸润、发展、转移有关,可作为一个预测胶质瘤侵袭转移能力的肿瘤标志物。PTEN蛋白在正常脑组织中的表达明显高于胶质瘤,且高级别组表达明显高于低级别组,提示PTEN基因突变或缺失在胶质瘤的发生发展中起重要作用,且与肿瘤恶性分化程度密切相关,表明PTEN的失活预示着一个特殊的进展性的临床行为,在胶质瘤恶性进展中属于较晚发生的分子事件。     

Stathmin 在微血管内皮细胞的表达与胶质瘤恶性程度关系

目的:检测Stathmin在正常脑组织及不同级别胶质瘤微血管内皮细胞中的表达情况。方法:利用结合CD105单克隆抗体的免疫磁珠内皮细胞分选系统特异性分选出68例胶质瘤微血管内皮细胞(其中低级别胶质瘤(WHO分级Ⅰ-Ⅱ)24例,高级别胶质瘤(WHO分级Ⅲ-Ⅳ)44例)和20例正常脑组织微血管内皮细胞。应用免疫组化、RT-PCR和Western blot检测Stathmin在胶质瘤微血管内皮细胞和正常脑组织微血管内皮细胞中的表达。结果:免疫组化证实Stathmin在正常脑组织微血管内皮细胞、低级别胶质瘤微血管内皮细胞和高级别胶质瘤微血管内皮细胞的表达百分率分别是20%,66%和95%(P<0.05)。RT-PCR和Western blot法检测显示,Stathmin在胶质瘤微血管内皮细胞中的表达明显增高。低级别胶质瘤组、高级别胶质瘤组分别与正常组比较,均有显著性差异(P<0.01);且低级别胶质瘤组与高级别胶质瘤组比较,有显著性差异(P<0.01),随着胶质瘤恶性程度的增加,Stathmin表达上调,具有统计学意义。结论:Stathmin在脑胶质瘤微血管内皮细胞中表达随肿瘤恶性程度增高而增加,可能为脑胶质瘤的生物治疗提供一个新靶点。     

人脑星形细胞瘤中p53，Fas／FasL的表达及其与凋亡关系的研究

目的：探讨细胞凋亡在星形细胞瘤中的作用及其与p53、Fas和Fas配体（Fas ligand,FasL）的关系。方法：对43例星形细胞瘤的标本分别进行HE染色,TUNEL及免疫组化分别标记p53,Fas和FasL。结果：高级别肿瘤和低级别肿瘤间的凋亡无显著差异（P〉0．05）。高级别星形细胞瘤的p53,Fas和FasL的表达均显著高于低级别肿瘤（P均〈0．05）。结论：突变型p53可作为评价星形细胞瘤生物学行为的参考指标。与低级别星形细胞瘤相比,高级别肿瘤中的细胞凋亡受到了抑制,且Fas与FasL的过表达对细胞凋亡可产生明显影响。     

人脑胶质瘤中CD147 和MMP-2 的表达及临床意义

目的:通过探讨CD147和MMP-2在人脑胶质瘤中的表达及临床意义,为临床治疗提供参考。方法:选择2010年1月至2015年5月本院手术切除并经病理诊断确诊的脑胶质瘤标本70例作为观察组,根据WHO分型,将其分为低级别组31例和高级别组39例。另选取20例脑外伤患者并作内减压切除的标本作为对照组。采用免疫组化SP法检测CD147与MMP-2蛋白的表达,RT-PCR检测CD147mRNA表达,并探讨CD147表达与患者预后的关系。结果:观察组中CD147阳性表达率为75.71%,MMP-2阳性表达率74.29%,两者存在相关性(r=0.870,P0.05)。高级别组和低级别组CD147mRNA表达水平均强于对照组,差异有统计学意义(均P0.05),且高级别高于低级别组,差异有统计学意义(P0.05)。复发患者CD147阳性表达率显著高于非复发患者,差异有统计学意义(P0.05);生存时间5年患者CD147阳性表达率显著高于生存时间≥5年患者,差异有统计学意义(P0.05)。结论:人脑胶质瘤中CD147和MMP-2的表达与肿瘤恶性程度和患者预后密切相关,可为患者临床预后判断和临床治疗提供参考。     

人巨细胞病毒IE1-72蛋白在胶质瘤中的表达及意义

目的:探讨人巨细胞病毒(HCMV)立刻早期基因1-72(IE1-72)蛋白在胶质瘤中的表达水平以及HCMV感染与胶质瘤发生的病因学关系。方法:采用免疫组化方法检测HCMV IE1-72蛋白在125例人脑胶质瘤组织及10例正常人脑组织中的表达,分析其表达水平与胶质瘤临床病理学特征的关系。结果:IE1-72蛋白在胶质瘤组织中的表达水平明显高于正常人脑组织(P=0.000);IE1-72蛋白免疫染色强度随胶质瘤病理级别的升高而明显增强(r=0.310,P=0.000),其在高恶性度胶质瘤中的染色强度明显强于低恶性度胶质瘤(P=0.004);IE1-72蛋白染色强度与胶质瘤患者的年龄存在正相关(r=0.234,P=0.009),而与胶质瘤患者的性别(r=0.038,P=0.675)以及肿瘤部位(r=0.086,P=0.341)无明显相关性。结论:HCMV感染及其蛋白IE1-72表达可能与人脑胶质瘤的发生和发展密切相关,但其确切的致瘤机制尚需进一步研究。     

人脑胶质瘤细胞中GDNF 基因启动子1 区甲基化状态的研究

目的:观察GDNF启动子1区在人脑胶质瘤细胞中的甲基化修饰状态,以期探讨其对于GDNF在胶质瘤中高表达的影响。方法:基因测序检测10例胶质瘤与5例正常脑组织中GDNF基因序列,比较其基因是否有突变发生;重亚硫酸盐修饰后基因测序检测20例胶质瘤(10例低级别和10例高级别)与5例正常脑组织中GDNF启动子1区甲基化修饰状态。结果:GDNF启动子1区基因在胶质瘤中没有发生突变;GDNF启动子1区甲基化修饰在正常脑组织、低级别、高级别中发生率分别为72.25%、86.25%、86.75%。在胶质瘤中的甲基化修饰水平比正常脑组织明显增高(P<0.05),而高低级别之间无显著性差异。结论:在胶质瘤细胞中,GDNF启动子1区发生了高甲基化修饰,这种修饰很可能会影响GDNF基因的表达。     

磁共振波谱分析在颅脑胶质瘤分级中的应用研究

目的 分析脑胶质瘤的氢质子磁共振波谱（proton magnetic resonance spectroscopy,1H-MRS）表现及其临床意义;探讨脑胶质瘤的1H-MRS特点与其病理级别相关性.方法 搜集经临床手术、病理证实的脑胶质瘤病例49例,按照WHO诊断标准分成两组：低级别脑胶质瘤组、高级别脑胶质瘤组.所有患者在术前行1H-MRs检查,均在MR非增强成像的基础上获得.使用Philips Achieva 1.5T超导磁共振扫描仪,单体素或多体素扫描,点分辨法,检测不同区域代谢物变化.结果 脑胶质瘤的1H-MRS表现：肌酸（Cr）轻度下降,N-乙酰天门冬氨酸（NAA）显著下降,胆碱（Cho）显著增高.低、高级别脑胶质瘤的肿瘤组织与对侧止常脑组织的NAA、Cho、NAA/Cr、NAA/Cho值存在显著性差异（P〈0.05）;低级别和高级别脑胶质瘤的肿瘤组织的NAA/Cr、NAA/Cho值存在显著性差异（P〈0.05）.脑胶质瘤的NAA/Cho、Cho/Cr、NAA/Cr值与病理级别相关,其中NAA/Cho和NAA/Cr值反映肿瘤级别较稳定;NAA/Cr、NAA/Cho值呈负相关关系,Cho/Cr值呈正相关关系.结论 ：1H-MRS结合MKI能提高脑胶质瘤术前诊断的准确性.1H-MRS能对胶质瘤进行分级,反映胶质瘤代谢特性以及肿瘤生长潜能.     

siRNA抑制stathmin表达对高级别胶质瘤血管内皮细胞迁移的影响

目的：探讨siRNA抑制Stathmin表达对高级别胶质瘤微血管内皮细胞侵袭性的影响。方法：利用结合CDl05单克隆抗体的免疫磁珠内皮细胞分选系统特异性分选出22例高级别胶质瘤微血管内皮细胞（其中8例III级胶质瘤,14例Ⅳ级胶质瘤,13例男性和9例女性组成）。应用siRNA技术抑制高级别胶质瘤血管内皮细胞中Stathmin表达,Transwell侵袭实验检测Stathmin基因沉默对高级别胶质瘤血管内皮细胞迁移的影响。结果：采用RNA干扰Stathmin的高级别胶质瘤微血管内皮细胞中Stathmin的mRNA和蛋白表达均较对照组显著下降,而迁移细胞数也显著低于对照组（P〈0．01）。结论：通过siRNA抑制高级别胶质瘤血管内皮细胞中Stathmin表达可抑制其迁移。     

3.0T 1H-MRS对脑胶质瘤及脑转移瘤的鉴别诊断

目的：利用3.0T氢质子磁共振波谱对胶质瘤和转移瘤的肿瘤组织区、瘤周水肿区进行细胞代谢物水平的检测,试图找出胶质瘤和脑转移瘤的鉴别诊断的依据,以及胶质瘤高、低级别组间的差别。方法：对经病理证实的20例高级别胶质瘤组、16例低级别胶质瘤组和19例脑转移瘤组患者,先行MRI平扫及增强扫描,波谱均在增强扫描的基础上获得,使用MR点分辨波谱序列,检测肿瘤组织区、瘤周水肿组织区NAA/Cr、Cho/Cr、NAA/Cho、NAA、Cho、Cr、Lip/Lac等值,进行比较。结果：（1）高级别胶质瘤与转移瘤在肿瘤组织区NAA/Cr代谢物浓度的比值有统计学意义。（2）高、低级别胶质瘤肿瘤组织内Cho/Cr比值有统计学意义。（3）转移瘤与高、低级别胶质瘤在瘤周水肿区NAA/Cr,以及低级别胶质瘤与转移瘤Cho/Cr代谢物浓度的比值有统计学意义;高级别胶质瘤与转移瘤瘤周区NAA代谢物浓度有明显差异。（4）胶质瘤高、低级别组间在肿瘤周围区NAA峰、Cho峰及NAA/Cho Cho/Cr代谢物浓度比值有统计学意义。（5）高级别胶质瘤和转移瘤分别与低级别胶质瘤在肿瘤组织区及瘤周水肿区Lip/Lac有显著性差异（P〈0.01）。结论：利用氢质子波谱可对胶质瘤和转移瘤进行鉴别诊断;Cho/Cr及NAA/Cho比值可对胶质瘤进行分级;Lip/Lac峰的出现与肿瘤的恶性度呈正相关,但不特异。     

Increased expression of microRNA-9 predicts an unfavorable prognosis in human glioma

microRNA-9 (miR-9) has been found to be upregulated along with tumor progression of gliomas by microarray-based expression profiling, and also be strongly linked to glioblastoma subtypes. However, its prognostic value in glioma is still elusive. miR-9 expression in human gliomas and nonneoplastic brain tissues was measured by real-time quantitative RT-PCR assay. miR-9 expression in glioma tissues was significantly higher than that in corresponding nonneoplastic brain tissues (P < 0.001). The increased expression of miR-9 was more frequently observed in glioma tissues with high WHO grade than those with low WHO grade tissues (P = 0.001). The expression levels of miR-9 in glioma tissues with low Karnofsky performance score (KPS) were also significantly higher than those with high KPS (P = 0.008). Moreover, the overall survival of glioma patients with high miR-9 expression was obviously lower than that with low miR-9 expression (P < 0.001). Multivariate analysis further showed that high miR-9 expression was an independent prognostic factor for overall survival in glioma patients (P = 0.01). More importantly, the subgroup analyses indicated that the overall survival of glioma patients with high WHO grade (III–IV) was significantly worse for high miR-9 expression group than for low miR-9 expression group (P < 0.001), but no significant difference was found for patients with low WHO grade (I–II). These findings suggest for the first time that the increased expression of miR-9 may play an important role in tumor progression in human gliomas. miR-9 might be a useful marker for predicting the clinical outcome of glioma patients, especially for advanced subtypes.     

Decreased expression of microRNA-200b is an independent unfavorable prognostic factor for glioma patients

Background and aimAs a member of the microRNA (miR)-200 family, miR-200b has been recognized as one of the fundamental regulators of epithelial–mesenchymal transition, chemosensitivity, cell proliferation, and cell cycle. Especially in glioma, miR-200b targets the CREB1 gene and suppresses the tumor cell growth in vitro. However, its involvement in human glioma has not yet been determined. The aim of this study was to investigate the clinical significance of miR-200b expression in this disease.MethodsmiR-200b expression in 266 pairs of human gliomas and matched nonneoplastic brain tissues was measured by real-time quantitative RT-PCR assay.ResultsCompared with nonneoplastic brain tissues, the expression level of miR-200b was significantly decreased in glioma tissues (tumor vs. normal: 2.87 ± 2.05 vs. 8.78 ± 2.50, P < 0.001). Of 266 patients with gliomas, 166 (62.41%) were in low miR-200b expression group. In addition, we found that the glioma tissues from high-grade tumors (grade III and IV) had much lower miR-200b expression than glioma tissues from low grade tumors (grade I and II). Moreover, the expression level of miR-200b was positively correlated with Karnofsky performance status (KPS) scores of glioma tissues. The results of a 60-month follow-up in 266 glioma patients further demonstrated that lower miR-200b expression was correlated with worse progression-free survival and overall survival in the patients with grade III and IV gliomas. Both univariate and multivariate analyses revealed that miR-200b was an independent prognostic indicator for glioma.ConclusionThese findings prove that the decreased expression of miR-200b may be associated with malignant tumor progression and poor prognosis in patients with gliomas, suggesting the potential role of miR-200b in glioma management. miR-200b may be a novel and valuable signature for predicting the clinical outcome of patients with gliomas.     

Oncogenic reg IV is a novel prognostic marker for glioma patient survival

ABSTRACT: Aim The aberrant expression of regenerating islet-derived family member, 4 (Reg IV) has been found in various human cancers. However, the roles of Reg IV gene and its encoding product in human glioma have not been clearly understood. Therefore, the aim of this study was to investigate the clinicopathological significance of Reg IV expression in glioma. METHODS: Reg IV mRNA and protein expression in human gliomas and non-neoplastic brain tissues were respectively detected by real-time quantitative RT-PCR assay, Western blot, and immunohistochemistry. The association of Reg IV immunostaining with clinicopathological factors and prognosis of glioma patients was also statistically analyzed. RESULTS: Reg IV mRNA and protein expression levels in glioma tissues were both significantly higher than those in the corresponding non-neoplastic brain tissues (both P?相似文献   

Syndecan-1 expression in human glioma is correlated with advanced tumor progression and poor prognosis

Syndecan-1 has been implicated in tumorigenesis and progression of various human malignancies. Recent studies have demonstrated that syndecan-1 may have a different function and biological activity depending on the specific tumor type. Therefore, the aim of this study was to investigate the clinical significance of syndecan-1 in human gliomas. One hundred and sixteen glioma patients (26 World Health Organization (WHO) grade I, 30 WHO grade II, 30 WHO grade III, and 30 WHO grade IV) and 15 normal brain specimens acquired from 15 patients undergoing surgery for epilepsy as control were collected. Immunohistochemistry assay, quantitative real-time PCR and Western blot analysis were carried out to detect the expression of syndecan-1 at gene and protein levels in glioma samples with different WHO grades. Syndecan-1 gene and protein levels were both higher in glioma tissues compared to controls (both P < 0.001). In addition, its expression levels increased with ascending tumor WHO grades according to the results of immunohistochemistry assay, quantitative real-time PCR and Western blot analysis. Moreover, the survival rate of syndecan-1-positive patients was significantly lower than that of syndecan-1-negative patients (P = 0.006). We further confirmed that the increased expression of syndecan-1 was an independent prognostic indicator in glioma by multivariate analysis (P = 0.01). Our data suggest for the first time that the increased expression of syndecan-1 at gene and protein levels is correlated with advanced tumor progression and poor outcome in patients with glioma. Syndecan-1 might serve as a potential prognosis predictor of this dismal tumor.     

神经胶质瘤中PTEN、Ki-67和HIF-1α的表达及临床意义

目的:抑癌基因PTEN、癌基因Ki-67及HIF-1α对多种人类肿瘤的恶性进展均起重要的调控作用。本研究主要探讨PTEN、Ki-67及HIF-1α在人脑胶质瘤中的表达及临床意义,为胶质瘤患者预后的判定、分子病理学的诊断、基因靶向的治疗奠定理论基础。方法:在83例原发性人脑胶质瘤组织样本中,通过免疫组化的方法检测PTEN、Ki-67及HIF-1α的表达情况,并分析其表达相互间及其表达与肿瘤恶性级别之间的相关性。结果:在正常脑组织中,PTEN的表达均为阳性,Ki-67的表达均为阴性,10%(1/10)的样本HIF-1α的表达为阳性。在胶质细胞瘤中,PTEN的表达显著降低(P=0.001),而Ki-67(P0.001)和HIF-1α(P=0.001)的表达明显增高。随肿瘤恶性级别的增高,PTEN的表达呈降低趋势(P0.001),而Ki-67和HIF-1α的表达呈升高趋势(两者P均0.001)。相关性分析表明,PTEN的表达与Ki-67和HIF-1α的表达呈负相关(r值分别为-0.289和-0.304;P值分别为0.008和0.005),Ki-67的表达与HIF-1α的表达呈正相关(r=0.833;P0.001)。结论:胶质瘤组织缺乏抑癌基因PTEN蛋白的表达,而高度表达癌基因Ki-67和HIF-1α。抑癌基因PTEN表达减少或失活,癌基因Ki-67和HIF-1α的过表达对胶质瘤恶性进展可能起到至关重要的作用。PTEN、Ki-67和HIF-1α蛋白的联合检测对胶质瘤恶性程度和预后的判定有十分重要的临床意义。     

Sialyllactotetraosylceramide, a Ganglioside Marker for Human Malignant Gliomas

The ganglioside composition of surgically removed human glioma tissue was shown to differ from that of normal adult brain tissue. First, it contained reduced amounts of the major normal brain gangliosides of the gangliotetraose series. Second, it contained increased proportions of gangliosides not detected in normal brain tissue. One of these was isolated and established as being sialyllactotetraosylceramide 3'-isoLM1. Radioimmunoassay for this ganglioside antigen in human glioma tissue revealed that 14/14 specimens of grades III and IV were positive but only 1/4 of grade II. Normal brain tissue was negative. These results suggest that sialyllactotetraosylceramide is a marker for human malignant gliomas.